Thyme Care raises $125M+ as Robin Shah builds an oncology parent company
Thyme Care, valued above $2B, is using capital from Morgan Health, Humana and CVS Health Ventures to develop standalone businesses for biosimilars and clinical-trial enrollment.
By RuntimeWire Staff · Published
Primary source: PR Newswire
Why it matters
Thyme Care has put its existing oncology-navigation operation under a parent company that plans to build independent businesses around biosimilar adoption and clinical-trial enrollment. The structure gives Robin Shah a vehicle to apply six years of oncology relationships and operating experience to narrower problems beyond navigation.
Nashville-based Thyme Care announced on September 2nd that it raised more than $125 million at a valuation above $2 billion.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.